

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Voclosporin with immunosuppressive therapies for treating lupus nephritis ID3962

Provisional Stakeholder List

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> • Otsuka Pharmaceuticals (voclosporin) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • AOFAC Foundation • Arthritis Action • Arthritis & Musculoskeletal Alliance • British Sjögren's Syndrome Association • Genetic Alliance UK • Gene People • Kidney Care UK • Lupus Trust • Lupus UK • National Kidney Federation • National Rheumatoid Arthritis Society • Polycystic Kidney Disease Charity • Raynaud's & Scleroderma Association • South Asian Health Foundation • Specialised Healthcare Alliance <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Association of Renal Technologists • British Association of Urological Nurses • British Association of Urological Surgeons • British Geriatrics Society • British Isles Lupus Assessment Group • British Renal Society • British Society for Allergy and Clinical Immunology • British Society for Haematology • British Society for Rheumatology • British Society of Haemostasis and Thrombosis • Clinical Leaders of Thrombosis • Primary Care Rheumatology Society • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal Society of Medicine 	<p><u>General</u></p> <ul style="list-style-type: none"> • All Wales Therapeutics and Toxicology Centre • Allied Health Professionals Federation • Association of Renal Industries • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Confederation • NHS England Specialised Rheumatology Clinical Reference Group • Scottish Medicines Consortium • Welsh Health Specialised Services Committee <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> • Accord Healthcare (mycophenolate mofetil, prednisolone) • Aspen (azathioprine) • ADVANZ Pharma (prednisolone) • Astellas Pharma (tacrolimus) • Baxter Healthcare (cyclophosphamide) • Chiesi (tacrolimus) • Dexcel Pharma (ciclosporin) • Ennogen Pharma (azathioprine) • Mylan (azathioprine, ciclosporin) • Napp Pharmaceuticals (rituximab) • Nova Laboratories (azathioprine) • Novartis Pharmaceuticals (ciclosporin, mycophenolic acid as mycophenolate sodium)

Provisional stakeholder list for the single technology appraisal of voclosporin with immunosuppressive therapies for treating lupus nephritis ID3962

Issue date: November 2021

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • Society for DGH Nephrologists • Society for Vascular Technology • Society of Vascular Nurses • UK Clinical Pharmacy Association • UK Kidney Association • UK Renal Pharmacy Group • United Kingdom Primary Immunodeficiency Network • Urology Foundation • Vascular Society of Great Britain and Ireland <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health and Social Care • NHS Bath and North East Somerset CCG • NHS England • NHS Fylde & Wyre CCG • Welsh Government 	<ul style="list-style-type: none"> • Pfizer (methylprednisolone, rituximab) • Phoenix Labs (prednisolone) • Relonchem (azathioprine) • Roche Products (mycophenolate mofetil, rituximab) • Sandoz (cyclophosphamide, mycophenolic acid as mycophenolate sodium, rituximab, tacrolimus) • Strides Pharma UK (azathioprine) • Teva Pharma (mycophenolate mofetil) • Tillomed Laboratories (azathioprine, mycophenolate mofetil) • Wockhardt (prednisolone) • Zentiva (prednisolone) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Antithrombotic Trialists' Collaboration • British Epidermo-Epidemiology Society • Cochrane Kidney and Transplant Group • Cochrane UK • Cochrane Vascular Disease • Genomics England • Kidney Research UK • MRC Clinical Trials Unit • National Institute for Health Research • Thrombosis Research Institute <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> • Public Health Wales • UK Health Security Agency

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Appraisal Document (FAD).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Appraisal Document (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.

¹ Non company consultees are invited to submit statements relevant to the group they are representing.